Gastrointestinal dysfunction

Boruzu is the first ready-to-use bortezomib injection for multiple myeloma and mantle cell lymphoma. Credit: SmartPhotoLab/Shutterstock. Amneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or intravenous administration, offering a ready-to-use option for patients with multiple myeloma and mantle cell lymphoma in the US. Boruzu is the first ready-to-use bortezomib injection for multiple myeloma and mantle cell lymphoma , and lowers the compounding preparation process needed for administration. A proteasome inhibitor, Boruzu references branded Velcade, a lyophilised powder that needs reconstitution before usage. Shilpa has created the molecule, while Amneal will handle the manufacturing and commercialisation of the product. The most commonly reported adverse events for Boruzu in clinical studies have been anaemia, anorexia, asthenic conditions, diarrhoea, euralgia, gastrointestinal issues, leukopenia, neutropenia, peripheral neuropathy, psychiatric disorders, pyrexia, reduced appetite and thrombocytopenia. Amneal pharmaceutical biosimilars and branded oncology senior vice-president Sean McGowan stated: “As we advance our broader strategy to build a leading injectables portfolio with durable, high-impact complex products, we are excited to announce the US launch of Boruzu in our oncology portfolio. “This ready-to-use injectable marks a significant innovation for our customers by streamlining pharmacy preparation steps for clinicians while now carrying a unique J-code to facilitate reimbursement.” Amneal is a biopharmaceutical company based in Bridgewater, US. Through its affordable medicines segment, the company focuses on widening complex product categories as well as therapeutic areas, which include biosimilars and injectables. In its speciality segment, Amneal has a branded pharmaceutical portfolio focusing mainly on endocrine and central nervous system disorders. The company distributes pharmaceuticals and other products to the federal government of the US, as well as to institutional and retail markets, via its AvKARE segment. An integrated pharmaceutical group, Shilpa has business interests in peptides, oncology and non-oncology active pharmaceutical ingredients, differentiated finished dosage formulations and polymers. It also offers contract development and manufacturing organisation services to pharmaceutical firms, supported by research and development and manufacturing capabilities. In August 2024, the US Food and Drug Administration (FDA) approved Amneal’s Crexont extended-release capsules for treating Parkinson’s disease.

TRUMBULL, Conn., March 13, 2025 (GLOBE NEWSWIRE) -- The Rett Syndrome Research Trust (RSRT), the organization working to cure Rett syndrome, is pleased to announce that Amy Gilliland, President of General Dynamics Information Technology (GDIT), has joined its Board of Trustees. Amy’s daughter, Ashley, who was diagnosed with Rett syndrome in 2015, is the inspiration behind her drive to help find a cure for the 350,000 children and adults living with this devastating neurological disorder worldwide. “I’m thrilled to join the Board of Trustees and get even closer to the Reverse Rett mission,” says Amy Gilliland. “As a parent of a child living with Rett syndrome—like so many others leading and advising the RSRT— I share their dedication and urgency to find a cure. RSRT is an organization that delivers results. I am confident Rett syndrome can be eradicated, and I am excited to support the research that will get us there.” Amy brings significant experience in strategy, business growth, and leadership. As president of GDIT she oversees an $8.7 billion global technology enterprise. Gilliland has more than 25 years of public sector experience including nearly two decades in leadership positions at General Dynamics and service in the U.S. Navy. Amy has a longstanding commitment to RSRT and contributing to advance Rett research. Since 2018, she has spearheaded Reverse Rett DC, an annual fundraising and awareness event that has raised over $2 million for RSRT research. “We’re so fortunate to have Amy joining our Board,” says Monica Coenraads, RSRT’s Founder and Chief Executive Officer. “Her business acumen, leadership skills, and wide-ranging experience, along with her remarkable dedication to our cause will be invaluable to the Board and to RSRT. I know for Amy advancing Rett research is a family affair. Her husband, John, and son, Patrick, and youngest daughter, Elizabeth are as passionate as she is about our mission and I thank them, too, for their roles in Reverse Rett DC, and their commitment to Ashley and all with Rett syndrome.” About Rett SyndromeRett Syndrome is a genetic childhood neurological disorder caused by random mutations of the MECP2 gene on the X chromosome. It predominantly affects girls but can rarely also affect boys. Its symptoms typically become apparent between the ages of 12 to 18 months. Rett syndrome is devastating as it deprives young children of speech, hand use, and normal movement often including the ability to walk. As the children enter childhood the disorder brings anxiety, seizures, tremors, breathing difficulties, and severe gastrointestinal issues. While their bodies suffer, it is believed that their cognitive abilities remain largely intact. Although most children survive to adulthood, they require total round-the-clock care. About the Rett Syndrome Research Trust The Rett Syndrome Research Trust, a non-profit organization, began in 2008 at Rett parent Monica Coenraads’ kitchen table. RSRT was founded on three simple but powerful truths: children and adults with Rett syndrome are suffering and we must be their voices and their advocates; Rett syndrome is, remarkably, reversible in mouse models of the disorder; and, with continued research progress and sufficient funding, science holds the potential to translate that reversal in mice to a reversal in people. RSRT, which is the only organization exclusively focused on advancing genetic-based cures for Rett, is the largest funder of Rett research worldwide, with almost $110 million raised since its founding. Multiple clinical trials in gene therapy for Rett syndrome are now underway, all possible because of RSRT-funded research. In 2024 RSRT launched a $40 million initiative, Roadmap to Cures, with a goal to bring three genetic medicines, beyond the current gene therapies, to clinical trials by 2028. RSRT’s mission is clear, urgent, and personal: to cure Rett syndrome and transform the lives of the people we love. To learn more, please visit www.reverserett.org. Follow us on Facebook, Instagram and YouTube. Contact:Amanda BreedingScient PRamanda@scientpr.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/992d3595-12a0-4c09-8762-7e28bd061583

Young Scientists Shine at 5th Annual NOSTER & Science Microbiome Prize Ceremony KYOTO, Japan, Nov. 15, 2024 /PRNewswire/ -- Noster Inc. proudly hosted the 5th NOSTER & Science Microbiome Prize Symposium and Awards Ceremony in partnership with the American Association for the Advancement of Science (AAAS), publishers of the renowned Science journal. The events, held on October 10 and 11, 2024, highlighted the achievements of emerging leaders in microbiome research. The Grand Prize was awarded to Kazuki Nagashima of Stanford University, while Lina Yao and Brittany Needham were the finalists. On October 10, the Symposium at NOSTER's Kyoto headquarters featured this year's winners, who shared insights on their pioneering discoveries related to the gut microbiome and its impact on health. Topics covered included the intricate interactions between gut bacteria, host organisms, and immune cells, as well as the potential of microbiome-based therapies. The Ceremony on October 11, held at the Park Hyatt Kyoto, was attended by NOSTER CEO Kohey Kitao, Science Publisher Bill Moran, Science Senior Editor Caroline Ash, and leading researchers from Japan. This year's selection panel chose Kazuki Nagashima as the Grand Prize winner for his groundbreaking research on the effects of gut bacteria on T cells. Pioneering Discoveries in Microbiome Research Recent advances in microbiome research have unveiled significant links between gut bacteria and various diseases such as cancer, immune disorders, and gastrointestinal issues. The expanding field of metabolomics is shedding light on how microbial metabolites may influence disease mechanisms. Ongoing research is expected to lead to novel therapies that target the gut microbiome. NOSTER is committed to supporting young scientists and fostering transformative breakthroughs in this field through the NOSTER & Science Microbiome Prize. Research Highlights of the 2024 Awardees Kazuki Nagashima, winner of the Grand Prize, developed a method to identify the effects of gut bacteria on T cells, earning the 2024 NOSTER & Science Microbiome Prize Grand Prize. His work overturned previous theories by demonstrating that T cells, a type of immune cell, can recognize and respond to multiple types of bacteria. Finalist Lina Yao, conducted research aiming to develop new treatments for inflammatory bowel disease and autoimmune disorders by investigating the effects of bile acids produced by gut bacteria on immune cells. Finalist Brittany Needham, discovered that a substance called 4EPS produced by gut bacteria is present in high levels in the plasma of children with autism spectrum disorder. Her research focuses on how gut bacterial metabolites affect brain function by targeting the gut-brain axis. About the NOSTER & Science Microbiome Prize Applications for the 2025 NOSTER & Science Microbiome Prize are open from October 15, 2024, to February 14, 2025. The prize is open to researchers who have earned an M.D., Ph.D., or M.D./Ph.D. within the past 10 years. For more details Company Overview Name: Noster Inc. CEO: Kohey Kitao Headquarters: 35-3 Kamikainocho, Mukomachi, Kyoto, Japan Business: Research, development, and sales of biopharmaceuticals and functional foods Website: Contact Information Public Relations: Nanami Akatsuka Tel: 075-921-5303 / Fax: 075-924-2702 Email: [email protected] SOURCE Noster Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED